| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
The primary target of 2-Piperidone is CYP2E1, for which it serves as a biomarker of enzyme activity. As an endogenous metabolite, it may interact with various physiological pathways. Piperidine derivatives, which include 2-piperidone, are utilized in various therapeutic applications such as anticancer treatments. The compound also acts as a bronchodilator, opposing ileum contractions induced by histamine better than acetylcholine. These targets make it relevant for research in drug metabolism, respiratory function, and therapeutic applications.
|
|---|---|
| ln Vitro |
In vitro, 2-Piperidone demonstrates bronchodilator activity by causing dilatation of bronchial smooth muscles. It opposes ileum contractions induced by histamine more effectively than acetylcholine. As a biomarker for CYP2E1 activity, it is measured in vitro to assess enzyme function in liver microsomes or cell-based systems. The compound's cytotoxic properties against cancer cells have also been explored. These in vitro activities support its use in pharmacology, drug metabolism, and cancer research.
|
| ln Vivo |
In vivo, 2-Piperidone has been shown to increase PCT through dilatation of bronchial smooth muscles, demonstrating bronchodilator effects. Some 3,3-disubstituted 2-piperidinones possess potent anticonvulsant activity in vivo. As an endogenous metabolite, it is naturally present in mammalian systems. The compound is used in research to study CYP2E1 activity and its role in drug metabolism. Its potential therapeutic applications in respiratory and neurological disorders require further investigation.
|
| Enzyme Assay |
In vitro enzyme assays for 2-Piperidone involve measuring CYP2E1 activity using liver microsomes or recombinant enzymes. The compound is used as a biomarker to assess enzyme function, with concentrations typically ranging from 0.1-100 μM. CYP2E1 activity is measured using specific substrates (e.g., chlorzoxazone) and analyzing metabolite formation by HPLC or LC-MS. Bronchodilator activity is assessed using isolated smooth muscle preparations, where compound-induced relaxation is measured in response to histamine or acetylcholine challenge. All assays include appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for 2-Piperidone are conducted using various cell lines including cancer cells for cytotoxicity studies, and bronchial smooth muscle cells for respiratory research. Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. Cell viability is assessed using MTT assays. CYP2E1 activity is measured in cell lysates using specific substrates. For bronchodilator studies, isolated tissue preparations are used rather than cell cultures. Experiments include vehicle controls and positive controls (e.g., known bronchodilators or CYP2E1 inhibitors).
|
| Animal Protocol |
In vivo animal studies with 2-Piperidone are conducted in rodent models to assess bronchodilator and anticonvulsant activities. The compound is administered via intraperitoneal or oral routes at doses ranging from 0.25-0.5 mg/kg. Bronchodilator effects are assessed by measuring airway resistance or using isolated tissue preparations. Anticonvulsant activity is evaluated in seizure models. CYP2E1 activity is measured in liver samples to confirm biomarker utility. Each group consists of 6-10 animals with vehicle-treated controls. Data are analyzed using standard statistical methods.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Piperidone include its presence as an endogenous metabolite in mammalian systems. As a small, polar molecule (MW 99.13, C5H9NO), it is expected to have good water solubility and distribution in body fluids. The compound is metabolized through pathways involving CYP2E1, for which it serves as a biomarker. Elimination occurs via renal excretion. Its pharmacokinetics are influenced by CYP2E1 activity and renal function. Detailed PK parameters are available from metabolism studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-Piperidone indicate that it is generally well-tolerated at concentrations used for research. As an endogenous metabolite, it is expected to have a favorable safety profile. No significant toxicity has been reported in animal studies at typical research doses. However, comprehensive toxicological studies are limited. As with all research chemicals, appropriate safety precautions should be taken during handling, and the compound should be used only for in vitro and animal research purposes.
|
| Additional Infomation |
grayish-black, irregularly shaped, lumpy solid. Used in the manufacture of acetylene and steelmaking. Piperidin-2-one is a δ-lactam, a compound in which piperidine is substituted at the 2-position with a carbonyl group. It is an EC 1.2.1.88 (L-glutamate γ-semialdehyde dehydrogenase) inhibitor. It is a piperidinone compound and also a δ-lactam. 2-Piperidinone has been reported in Streptomyces antioxidans, Dichilus gracilis, and several other organisms with relevant data.
2-Piperidone is an endogenous metabolite and cyclic lactam that serves as a biomarker for CYP2E1 activity. It is used as an intermediate in chemical synthesis and has demonstrated bronchodilator activity. Some derivatives possess anticonvulsant properties. The compound is utilized in research on drug metabolism, respiratory function, and therapeutic applications including anticancer treatments. It is not approved for clinical therapeutic use and is intended for research purposes only. |
| Molecular Formula |
C₅H₉NO
|
|---|---|
| Molecular Weight |
99.13
|
| Exact Mass |
99.068
|
| CAS # |
675-20-7
|
| Related CAS # |
25036-00-4
|
| PubChem CID |
12665
|
| Appearance |
Off-white to light yellow <38°C powder,>40°C liquid
|
| Density |
1.073
|
| Boiling Point |
256-262 ºC
|
| Melting Point |
38-40 °C(lit.)
|
| Flash Point |
147 ºC
|
| Vapour Pressure |
0.1±0.9 mmHg at 25°C
|
| Index of Refraction |
1.539
|
| LogP |
-0.45
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
80.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1[H]
|
| InChi Key |
XUWHAWMETYGRKB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H9NO/c7-5-3-1-2-4-6-5/h1-4H2,(H,6,7)
|
| Chemical Name |
piperidin-2-one
|
| Synonyms |
2 Piperidone 2 Piperidone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~1008.78 mM)
DMSO : ~100 mg/mL (~1008.78 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (25.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (25.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (25.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.0878 mL | 50.4388 mL | 100.8776 mL | |
| 5 mM | 2.0176 mL | 10.0878 mL | 20.1755 mL | |
| 10 mM | 1.0088 mL | 5.0439 mL | 10.0878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
